Who are Enlivex Ltd.'s major customers?

Enlivex Ltd. (ENLV) key customers include: CollPlant Biotechnologies Ltd., CollPlant Biotechnologies Ltd., Indaptus Therapeutics, Inc., Indaptus Therapeutics, Inc., Johnson & Johnson and 16 more. View the full customer network at chainsifter.com/chain/ENLV.

What sector is Enlivex Ltd. in?

Enlivex Ltd. (ENLV) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Enlivex Ltd. (ENLV) Supply Chain: 24 Verified Relationships

0Suppliers

21Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Enlivex Ltd. (ENLV) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

35Total relationships

1Distinct source URLs

14High confidence

0.775Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Enlivex Ltd. Suppliers

No suppliers on recordEnlivex Ltd. has not yet been matched to upstream suppliers in our database, or is still being processed.

Enlivex Ltd. Customers

Ticker	Name	Confidence	Evidence
CLGN	CollPlant Biotechnologies Ltd.	72%	fair value of share-based payment awards represent management’s best estimates, but the estimates involve inherent uncertainties and the application of management judgment. 84 Accrued clinical trial …
CLGN	CollPlant Biotechnologies Ltd.	72%	Reciprocal relationship from CLGN graph: Reciprocal relationship from ENLV graph: fair value of share-based payment awards represent management’s best estimates, but the estimates involve inherent un…
INDP	Indaptus Therapeutics, Inc.	72%	Reciprocal relationship from INDP graph: Reciprocal relationship from ENLV graph: Reciprocal relationship from INDP graph: Reciprocal relationship from ENLV graph: fair value of share-based payment a…
INDP	Indaptus Therapeutics, Inc.	72%	fair value of share-based payment awards represent management’s best estimates, but the estimates involve inherent uncertainties and the application of management judgment. 84 Accrued clinical trial …
JNJ	Johnson & Johnson	72%	fair value of share-based payment awards represent management’s best estimates, but the estimates involve inherent uncertainties and the application of management judgment. 84 Accrued clinical trial …
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from ENLV graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ENLV graph: fair value of share-based payment awa…
MCRB	Seres Therapeutics, Inc.	72%	Reciprocal relationship from MCRB graph: Reciprocal relationship from ENLV graph: Reciprocal relationship from MCRB graph: Reciprocal relationship from ENLV graph: fair value of share-based payment a…
MCRB	Seres Therapeutics, Inc.	72%	fair value of share-based payment awards represent management’s best estimates, but the estimates involve inherent uncertainties and the application of management judgment. 84 Accrued clinical trial …
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from ENLV graph: fair value of share-based payment awards represent management’s best estimates, but the estimates involve inherent unc…
MRK	Merck & Co., Inc.	72%	fair value of share-based payment awards represent management’s best estimates, but the estimates involve inherent uncertainties and the application of management judgment. 84 Accrued clinical trial …
BIOHARVEST-LTD	BIOHARVEST-LTD	62%	current or any future product candidates may not be considered medically necessary or cost-effective. If third-party payers do not consider a product to be cost-effective compared to other available …
BTIG-LLC	BTIG-LLC	62%	from the sale of property and equipment and assets classified as held for sale, from $2,293,000 in 2024 to $1,375,000 in 2025. 77 For the years ended December 31, 2025 and 2024, net cash provided by …
CAPITAL-RESOURCES	CAPITAL-RESOURCES	62%	Item 4.B. “Information on the Company — Business Overview–––– Sepsis Clinical Program.” Additionally, in connection with the closing of the Private Placement in November 2025, the Company established…
ELINNOVATION-LABS-LTD	ELINNOVATION-LABS-LTD	62%	flationary burn tied to platform volume. The RAIN Ecosystem Rain operates as a permissionless “Uniswap of prediction markets” on Arbitrum, enabling anyone to create public or private markets for fore…
ENLIVEX-POLAND-LIMITED-LIABILITY-COMPANY	ENLIVEX-POLAND-LIMITED-LIABILITY-COMPANY	62%	current or any future product candidates may not be considered medically necessary or cost-effective. If third-party payers do not consider a product to be cost-effective compared to other available …
ENLIVEX-THERAPEUTICS-INC	ENLIVEX-THERAPEUTICS-INC	62%	current or any future product candidates may not be considered medically necessary or cost-effective. If third-party payers do not consider a product to be cost-effective compared to other available …
ENLIVEX-THERAPEUTICS-R-D-LTD	ENLIVEX-THERAPEUTICS-R-D-LTD	62%	current or any future product candidates may not be considered medically necessary or cost-effective. If third-party payers do not consider a product to be cost-effective compared to other available …
ENLIVEX-THERAPEUTICS-RDO-LTD	ENLIVEX-THERAPEUTICS-RDO-LTD	62%	current or any future product candidates may not be considered medically necessary or cost-effective. If third-party payers do not consider a product to be cost-effective compared to other available …
JMP-SECURITIES-LLC	JMP-SECURITIES-LLC	62%	from the sale of property and equipment and assets classified as held for sale, from $2,293,000 in 2024 to $1,375,000 in 2025. 77 For the years ended December 31, 2025 and 2024, net cash provided by …
SECURITIES-INVESTOR-PROTECTION-CORPORATION	SECURITIES-INVESTOR-PROTECTION-CORPORATION	62%	ularly in foreign countries in which laws may not protect our proprietary rights as fully as in the United States and other developed economies. Moreover, if we lose any key personnel, we may not be …
SHARP-VISION-INC	SHARP-VISION-INC	62%	fair value of share-based payment awards represent management’s best estimates, but the estimates involve inherent uncertainties and the application of management judgment. 84 Accrued clinical trial …

Enlivex Ltd. Debt Obligations

Instrument	Description	Confidence	Evidence
ENLV-DEBT	Debt stack $32.6M	90%	Market cache reports total debt of $32.6M.
ENLV-DEBT-9307	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2013-12-31.
ENLV-DEBT-9306	Warrants outstanding: 1	90%	xbrl warrant detail from xbrl 2025-12-31.

Enlivex Ltd. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Enlivex Ltd..

Enlivex Ltd. Ownership

Holder	Name	Confidence	Evidence
ENLV-OWNER-HRT-FINANCIAL-LP	HRT Financial LP	95%	13F/ownership overlay lists HRT Financial LP; shares held 153,990; ownership 0.83%; value $161,689; as of 2025-12-31.
ENLV-OWNER-JANE-STREET-GROUP-LLC	Jane Street Group, LLC	95%	13F/ownership overlay lists Jane Street Group, LLC; shares held 74,082; ownership 0.40%; value $77,786; as of 2025-12-31.
ENLV-OWNER-VIRTU-FINANCIAL-LLC	Virtu Financial LLC	95%	13F/ownership overlay lists Virtu Financial LLC; shares held 47,381; ownership 0.26%; value $49,750; as of 2025-12-31.
ENLV-OWNER-UBS-GROUP-AG	UBS Group AG	95%	13F/ownership overlay lists UBS Group AG; shares held 34,988; ownership 0.19%; value $36,737; as of 2025-12-31.
ENLV-OWNER-INVESCO-LTD	Invesco Ltd.	95%	13F/ownership overlay lists Invesco Ltd.; shares held 60,920; ownership 0.33%; value $63,965; as of 2025-12-31.
ENLV-OWNER-XTX-TOPCO-LTD	Xtx Topco Ltd	95%	13F/ownership overlay lists Xtx Topco Ltd; shares held 61,800; ownership 0.33%; value $64,889; as of 2025-12-31.
ENLV-OWNER-TWO-SIGMA-INVESTMENTS-LP	Two Sigma Investments, LP	95%	13F/ownership overlay lists Two Sigma Investments, LP; shares held 195,126; ownership 1.05%; value $204,882; as of 2025-12-31.
ENLV-OWNER-MORGAN-STANLEY	Morgan Stanley	95%	13F/ownership overlay lists Morgan Stanley; shares held 200,627; ownership 1.08%; value $210,658; as of 2025-12-31.
ENLV-OWNER-RENAISSANCE-TECHNOLOGIES-LLC	Renaissance Technologies, LLC	95%	13F/ownership overlay lists Renaissance Technologies, LLC; shares held 313,628; ownership 1.69%; value $329,309; as of 2025-12-31.
ENLV-OWNER-BANK-OF-AMERICA-CORPORATION	Bank of America Corporation	95%	13F/ownership overlay lists Bank of America Corporation; shares held 85,098; ownership 0.46%; value $89,352; as of 2025-12-31.
ENLV-OWNER-DIAMETRIC-CAPITAL-LP	Diametric Capital, LP	90%	13F overlay lists Diametric Capital, LP as top holder; 36 tracked holders.

Enlivex Ltd. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
DYN	Dyne Therapeutics, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
PSNL	Personalis, Inc.	100.00	2
BLLN	BillionToOne, Inc.	100.00	2
ALC	Alcon Inc.	100.00	2
ATRA	Atara Biotherapeutics, Inc.	100.00	2
ANIK	Anika Therapeutics, Inc.	100.00	2
CSTE	Caesarstone Ltd.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
SNNUF	Smith & Nephew plc	100.00	2
ESTA	Establishment Labs Holdings Inc.	100.00	2
IMMP	Immutep Limited	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
AORT	Artivion, Inc.	100.00	2
BNR	Burning Rock Biotech Limited	100.00	2
BNRG	Brenmiller Energy Ltd	100.00	2
AVBP	ArriVent BioPharma, Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
ADAG	Adagene Inc.	100.00	2

Enlivex Ltd. Supply Chain